Enzo Biochem Price to Free Cash Flow Ratio 2010-2022 | ENZ

Historical price to free cash flow ratio values for Enzo Biochem (ENZ) since 2010. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Enzo Biochem Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2023-01-26 1.50 0.00
2022-10-31 2.14 $-0.46 0.00
2022-07-31 2.37 $-0.41 0.00
2022-04-30 2.55 $-0.25 0.00
2022-01-31 3.22 $-0.20 0.00
2021-10-31 3.44 $-0.19 0.00
2021-07-31 3.26 $-0.08 0.00
2021-04-30 3.07 $-0.19 0.00
2021-01-31 2.82 $-0.29 0.00
2020-10-31 1.82 $-0.39 0.00
2020-07-31 2.38 $-0.41 0.00
2020-04-30 3.02 $-0.35 0.00
2020-01-31 2.51 $0.21 11.73
2019-10-31 3.16 $0.02 150.48
2019-07-31 3.91 $-0.07 0.00
2019-04-30 3.47 $-0.04 0.00
2019-01-31 3.76 $-0.55 0.00
2018-10-31 3.32 $-0.28 0.00
2018-07-31 4.42 $-0.10 0.00
2018-04-30 6.00 $-0.02 0.00
2018-01-31 7.36 $0.03 253.79
2017-10-31 9.85 $0.02 456.02
2017-07-31 10.85 $-0.04 0.00
2017-04-30 8.80 $0.70 12.61
2017-01-31 6.68 $0.62 10.77
2016-10-31 6.10 $0.82 7.48
2016-07-31 6.97 $1.11 6.30
2016-04-30 4.98 $0.42 11.83
2016-01-31 4.74 $0.45 10.57
2015-10-31 3.72 $0.22 16.86
2015-07-31 3.00 $-0.12 0.00
2015-04-30 2.80 $-0.19 0.00
2015-01-31 3.15 $-0.10 0.00
2014-10-31 5.22 $-0.04 0.00
2014-07-31 4.80 $-0.06 0.00
2014-04-30 4.20 $-0.12 0.00
2014-01-31 2.81 $-0.27 0.00
2013-10-31 2.49 $-0.32 0.00
2013-07-31 2.18 $-0.28 0.00
2013-04-30 2.24 $-0.23 0.00
2013-01-31 2.89 $-0.21 0.00
2012-10-31 2.00 $-0.17 0.00
2012-07-31 1.50 $-0.19 0.00
2012-04-30 2.74 $-0.28 0.00
2012-01-31 2.55 $-0.28 0.00
2011-10-31 2.86 $-0.26 0.00
2011-07-31 3.84 $-0.25 0.00
2011-04-30 3.99 $-0.19 0.00
2011-01-31 4.96 $-0.36 0.00
2010-10-31 4.31 $-0.39 0.00
2010-07-31 4.60 $-0.44 0.00
2010-04-30 5.97 $-0.50 0.00
2010-01-31 4.74 $-0.38 0.00
2009-10-31 5.51 $-0.48 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.073B $0.107B
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.571B 9.49
GSK (GSK) United Kingdom $71.996B 8.97
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.433B 19.52
Ginkgo Bioworks Holdings (DNA) United States $3.414B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.676B 25.16
Biohaven (BHVN) United States $1.305B 0.00
Emergent Biosolutions (EBS) United States $0.671B 5.28
ADC Therapeutics SA (ADCT) Switzerland $0.359B 0.00
Ambrx Biopharma (AMAM) United States $0.083B 0.00
Gelesis Holdings (GLS) United States $0.028B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00